

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Moller et al.

Confirmation No.: 4545

Application No.: 10/531,120

Group Art Unit: 1647

Filed: April 11, 2005

Examiner: Hamud, Fozia M.

For: Treatment of Allergic Conditions By Use of IL-21

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant(s) hereby submit(s) __1__ sheet(s) listing references and other information for consideration by the Examiner in accordance with 37 C.F.R. 1.56, 1.97, and 1.98;

Except for US patent documents, a copy of each listed reference is enclosed or submitted herewith. Copyrighted material submitted with this Information Disclosure Statement may be delivered to the Government under license from the Copyright Clearance Center, Inc., or other rights holders – no further reproduction of such works is permitted.

Inclusion of any reference is not intended to constitute an admission that the reference is "prior art" unless it is specifically designated as such.

This Information Disclosure Statement is being filed **before** the mailing date of a first Office action on the merits. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Inc. Deposit Account No. 14-1447.

Applicant(s) respectfully request(s) that any references or other information listed above be made of record in this patent application. The Examiner is invited to call the undersigned if there are any questions concerning this submission or application.

Respectfully submitted,

Date: October 17, 2007

/Len S. Smith, Reg. No. 43,139/
Len S. Smith, Reg. No. 43,139
Novo Nordisk Inc.
Customer No. 23,650
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650
PATENT TRADEMARK OFFICE